[1] Hussein, O., Zidan, J., Abu Jabal, K., Shams, I., Szvalb, S., Grozovski, M., Bersudsky, I., Karry, R., & Aviram, M. (2012). Paraoxonase activity and expression is modulated by therapeutics in experimental rat nonalcoholic fatty liver disease. International Journal of Hepatology, 2012, 265305. https://doi.org/10.1155/2012/265305

[2] Meneses, M. J., Silvestre, R., Sousa-Lima, I., & Macedo, M. P. (2019). Paraoxonase-1 as a regulator of glucose and lipid homeostasis: impact on the onset and progression of metabolic disorders. International Journal of Molecular Sciences, 20(16), 4049. https://doi.org/10.3390/ijms20164049

[3] Taler-Verčič, A., Goličnik, M., & Bavec, A. (2020). The structure and function of paraoxonase-1 and its comparison to paraoxonase-2 and -3. Molecules, 25(24), 5980. https://doi.org/10.3390/molecules25245980

[4] Garrick, J. M., Dao, K., Costa, L. G., Marsillach, J., & Furlong, C. E. (2022). Examining the role of paraoxonase 2 in the dopaminergic system of the mouse brain. BMC Neuroscience, 23(1), 52. https://doi.org/10.1186/s12868-022-00738-4

[5] Harel, M., Aharoni, A., Gaidukov, L., Brumshtein, B., Khersonsky, O., Meged, R., Dvir, H., Ravelli, R. B., McCarthy, A., Toker, L., Silman, I., Sussman, J. L., & Tawfik, D. S. (2004). Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nature Structural & Molecular Biology, 11(5), 412–419. https://doi.org/10.1038/nsmb767

[6] Shunmoogam, N., Naidoo, P., & Chilton, R. (2018). Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance. Vascular Health and Risk Management, 14, 137–143. https://doi.org/10.2147/VHRM.S165173

[7] Bar-Rogovsky, H., Hugenmatter, A., & Tawfik, D. S. (2013). The evolutionary origins of detoxifying enzymes: the mammalian serum paraoxonases (PONs) relate to bacterial homoserine lactonases. The Journal of Biological Chemistry, 288(33), 23914–23927. https://doi.org/10.1074/jbc.M112.427922

[8] Deakin, S., Leviev, I., Gomaraschi, M., Calabresi, L., Franceschini, G., & James, R. W. (2002). Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. The Journal of Biological Chemistry, 277(6), 4301–4308. https://doi.org/10.1074/jbc.M107440200

[9] Huang, Y., Wu, Z., Riwanto, M., Gao, S., Levison, B. S., Gu, X., Fu, X., Wagner, M. A., Besler, C., Gerstenecker, G., Zhang, R., Li, X. M., DiDonato, A. J., Gogonea, V., Tang, W. H., Smith, J. D., Plow, E. F., Fox, P. L., Shih, D. M., Lusis, A. J., … Hazen, S. L. (2013). Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. The Journal of Clinical Investigation, 123(9), 3815–3828. https://doi.org/10.1172/JCI67478

[10] Franco-Pons, N., Marsillach, J., Joven, J., Camps, J., & Closa, D. (2008). Serum paraoxonase undergoes inhibition and proteolysis during experimental acute pancreatitis. Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract, 12(5), 891–899. https://doi.org/10.1007/s11605-008-0502-2

[11] Ayub, A., Mackness, M. I., Arrol, S., Mackness, B., Patel, J., & Durrington, P. N. (1999). Serum paraoxonase after myocardial infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 19(2), 330–335. https://doi.org/10.1161/01.atv.19.2.330

[12] Kulka M. (2016). A review of paraoxonase 1 properties and diagnostic applications. Polish Journal of Veterinary Sciences, 19(1), 225–232. https://doi.org/10.1515/pjvs-2016-0028

[13] Ikeda, Y., Suehiro, T., Inoue, M., Nakauchi, Y., Morita, T., Arii, K., Ito, H., Kumon, Y., & Hashimoto, K. (1998). Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism: Clinical and Experimental, 47(5), 598–602. https://doi.org/10.1016/s0026-0495(98)90246-3

[14] Witte, I., Foerstermann, U., Devarajan, A., Reddy, S. T., & Horke, S. (2012). Protectors or traitors: the roles of pon2 and pon3 in atherosclerosis and cancer. Journal of Lipids, 2012, 342806. https://doi.org/10.1155/2012/342806

[15] Mogarekar, M. R., & Chawhan, S. S. (2013). The determination of Q192R polymorphism of paraoxonase 1 by using non-toxic substrate p-nitrophenylacetate. Indian Journal of Human Genetics, 19(1), 71–77. https://doi.org/10.4103/0971-6866.112897

[16] Camps, J., Pujol, I., Ballester, F., Joven, J., & Simó, J. M. (2011). Paraoxonases as potential antibiofilm agents: their relationship with quorum-sensing signals in Gram-negative bacteria. Antimicrobial Agents and Chemotherapy, 55(4), 1325–1331. https://doi.org/10.1128/AAC.01502-10

[17] Ceron, J. J., Tecles, F., & Tvarijonaviciute, A. (2014). Serum paraoxonase 1 (PON1) measurement: an update. BMC Veterinary Research, 10, 74. https://doi.org/10.1186/1746-6148-10-74

[18] Bassu, S., Mangoni, A. A., Satta, R., Argiolas, D., Carru, C., & Zinellu, A. (2022). Paraoxonase and arylesterase activity of serum PON-1 enzyme in psoriatic patients: a systematic review and meta-analysis. Clinical and Experimental Medicine. Advance online publication. https://doi.org/10.1007/s10238-022-00818-z

[19] Costa, L. G., Cole, T. B., Vitalone, A., & Furlong, C. E. (2005). Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clinica Chimica Acta; International Journal of Clinical Chemistry, 352(1-2), 37–47. https://doi.org/10.1016/j.cccn.2004.09.019

[20] Fang, B. K., Dai, C. Y., Severance, S., Hwang, C. C., Huang, C. H., Hou, S. Y., Yeh, B. L., Gong, M. M., Chou, Y. H., Wang, J. J., & Wang, T. P. (2022). Sensitive assay for the lactonase activity of serum paraoxonase 1 (pon1) by harnessing the fluorescence turn-on characteristics of bioorthogonally synthesized and geometrically controlled chemical probes. Molecules (Basel, Switzerland), 27(8), 2435. https://doi.org/10.3390/molecules27082435

[21] Bradford M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 72(1-2), 248–254. https://doi.org/10.1006/abio.1976.9999

[22] Camps, J., Marsillach, J., & Joven, J. (2009). Measurement of serum paraoxonase-1 activity in the evaluation of liver function. World Journal of Gastroenterology, 15(16), 1929–1933. https://doi.org/10.3748/wjg.15.1929

[23] Mackness, M. I., Arrol, S., Abbott, C., & Durrington, P. N. (1993). Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis, 104(1-2), 129–135. https://doi.org/10.1016/0021-9150(93)90183-u

[24] Milaciu, M. V., Vesa, Ștefan C., Bocșan, I. C., Ciumărnean, L., Sâmpelean, D., Negrean, V., Pop, R. M., Matei, D. M., Pașca, S., Răchișan, A. L., Buzoianu, A. D., & Acalovschi, M. (2019). Paraoxonase-1 serum concentration and PON1 gene polymorphisms: relationship with non-alcoholic fatty liver disease. Journal of Clinical Medicine, 8(12), 2200. https://doi.org/10.3390/jcm8122200